What to Expect From Merck and Pfizer Earnings

Health and Healthcare

Published: April 27, 2015 3:22 pm

Last Updated: April 28, 2020 9:56 am

Pharmaceutical giants Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) are both releasing their first quarter financial results Tuesday before the markets open. Each of these companies is a leader in the health care sector which has had a strong year so far.

Comparatively Merck has a market cap of roughly $162 billion while Pfizer has a market cap of $213 billion. So far on the year, Merck shares have gained 2.3% and Pfizer shares have gained over 14%.

Merck has consensus estimates from Thomson Reuters of $0.74 in earnings per share (EPS) on $8.99 billion in revenue. The same period from last year had $0.88 in EPS on $10.26 billion in revenue.

This stock has been hit hard since printing a high in late January, and it may be offering new investors a very good entry point. It also remains a leading healthcare company that is on the focus lists of many top analyst firms. The company’s numerous prescription medicines, vaccines, biologic therapies and consumer care and animal health products are provided to customers in more than 140 countries.

Shares of Merck traded down 0.9% at $57.09. The stock has a consensus analyst price target of $63.85 and a 52-week trading range of $52.49 to $63.62.

Pfizer has consensus estimates of $0.49 in EPS on $10.73 billion in revenue. The first quarter from the previous year had $0.57 in EPS on $11.30 billion in revenue.

The pharmaceutical giant is the fifth-best Dow gainer so far this year at 14.5%, while rival Merck is up less than 3%. Many investors are operating under the premise that Pfizer is on the path to break up into two, or maybe even into three, companies. Its 3.2% yield also remains a draw. Still, patent cliffs are a constant challenge, and they are forcing Pfizer and other drug giants to look for opportunities in emerging pharma, biotech and internationally.

Shares of Pfizer were down 1.6% at $34.71. The stock has a consensus analyst price target of $36.60 and a 52-week trading range of $27.51 to $35.53.

ALSO READ: 4 Biotech and Pharma Stocks Projected to Rise 50% to 100%

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.